TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study To Investigate The Safety And Efficacy Of CP- 690,550 In Patients With Moderate And Severe Ulcerative Colitis.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must be at least 18 years of age at screening~* Males and female patients with clinical diagnosis of ulcerative colitis ≥3 months prior to entry into the study.~* Male and female patients with active currently moderate to severe ulcerative colitis defined by Mayo score of ≥6~* Patients with endoscopic sub-score of ≥2 on the Mayo score determined within 7 days of baseline.~Exclusion Criteria:~* Diagnosis of Crohn's disease or diagnosis of indeterminate colitis~* Treatment naive subjects who have not had previous exposure to treatment for ulcerative colitis~* Patients that are currently receiving immunosuppressants, anti-TNFα therapy or interferon

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 15 mg BID (Type: EXPERIMENTAL): None
- 10 mg BID (Type: EXPERIMENTAL): None
- 3 mg BID (Type: EXPERIMENTAL): None
- 0.5 mg BID (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety Study of Mesenchymal Precursor Cells in Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~* Male and female subjects who are ≥ 18 and ≤ 80 years old~* Subjects diagnosed with type 2 diabetes at least one year prior to Screening and receiving a stable, therapeutic dose of metformin \> 1500 mg/day according to local prescribing information for at least 3 months prior to Screening or the highest tolerated dose \> 1000 mg/day documented in the subject's history~* HbA1c \> 7.0% and \< 10.5% at Screening~* C-peptide \> 0.8 ng/mL at Screening~* Body mass index (BMI) \> 22 and \< 45 kg/m2 at Screening~* Body weight \< 150 kg at Screening~Key Exclusion Criteria:~* Prior participation in any stem cell study~* Women who are pregnant, intending to become pregnant during the study period or currently lactating~* History of active substance abuse (including alcohol) within the past 2 years. Current alcohol abuse is defined as daily consumption of \>3 alcoholic beverage. Current cigarette smoking \> 10 cigarettes per day~* Severe hypoglycemia (defined as requiring third party assistance) or repeated and/or frequent hypoglycemia episodes (\> 2 episodes/week) within one month prior to Screening~* Patients receiving treatment for type 2 diabetes with diet and exercise alone, insulin therapy within 6 months of Screening except if used transiently for \< 7 days for intercurrent illness or any other anti-diabetic medication except metformin within 3 months of Screening~* Any concurrent medical condition/disorder or clinically symptomatic cardiovascular, gastrointestinal (including pancreatitis), renal, hematological, pulmonary, acute or chronic infectious disease, active retinal disease, or other disorder which in the Investigator's opinion would interfere with the subject's ability to complete the trial, would require administration of treatment that could affect the interpretation of the safety and efficacy variables or would preclude safe involvement in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Cohort 1 (Type: EXPERIMENTAL): MPC dose 1 or Placebo
- Cohort 2 (Type: EXPERIMENTAL): MPC dose 2 or Placebo
- Cohort 3 (Type: EXPERIMENTAL): MPC dose 3 or Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Guardix-solution for the Prevention of Postoperative Intestinal Adhesion and Intestinal Obstruction After Laparoscopic Pelvic Cavity Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men who were 50-75 years old and diagnosed with prostate cancer were eligible if they were scheduled to undergo laparoscopic pelvic surgery (radical prostatectomy).~Exclusion Criteria:~* any history of abdominal or pelvic surgery, hypersensitivity or an allergic reaction to the study material, pelvic lymph node dissection at the same time as prostatectomy, the presence of surgical site infection or contamination, a history of a medical disease causing bowel adhesion, or a history of severe drug allergies.

- Gender: MALE
- Minimum Age: 50 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- hyaluronic acid-carboxymethylcellulose treatment group (Type: EXPERIMENTAL): the HA/CMC treatment group after laparoscopic pelvic surgery
- control group (Type: NO_INTERVENTION): the HA/CMC non-treatment group after laparoscopic pelvic surgery

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Exploring the Efficacy and Safety of Rivaroxaban to Support Elective Percutaneous Coronary Intervention

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subject aged 18 years or more with no upper age limit and willing to comply with the protocol~* Symptomatic coronary artery disease due to undergo an elective (non-emergent) Percutaneous Coronary Intervention (PCI) on one or two lesions in the native coronary vessel(s). Cardiac standard troponin at baseline is within the normal limits~Exclusion Criteria:~* Conditions that may increase the risk of the PCI procedure~* Conditions that may increase the risk of bleeding~* Significant valvular heart disease~* Calculated creatinine clearance ≤30 mL/min~* Current use of anticoagulant drugs including Vitamin K antagonist (VKA), factor IIa or factor XA inhibitors~* Chronic treatment with non-steroidal anti-inflammatory drugs (NSAIDs)~* Chronic treatment with aspirin \> 100mg

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: ACTIVE_COMPARATOR): None
- Arm 2 (Type: EXPERIMENTAL): None
- Arm 3 (Type: EXPERIMENTAL): None
- Arm 4 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Simvastatin Effect on Inflammation and Endothelial Function After Myocardial Infarction

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Less than 24 hours after the onset of MI symptoms~* ST-segment elevation of a least 1 mm (frontal plane) or 2 mm (horizontal plane) in two contiguous leads~* Myocardial necrosis, as evidenced by increased CK-MB and troponin levels~Exclusion Criteria:~* Use of statins for at least 6 months prior the myocardial infarction

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- No lipid-lowering (Type: NO_INTERVENTION): No lipid-lowering treatment during the first 7 days and then simvastatin 20 mg/day for three additional weeks, till the endothelial function assessment
- Simvastatin 20 mg (Type: EXPERIMENTAL): Simvastatin 20 mg/day for 30 days, till the endothelial function assessment
- Simvastatin 40 mg (Type: EXPERIMENTAL): Simvastatin 40 mg/day for 7 days and then switched to simvastatin 20mg/day for additional 3 weeks, till the endothelial function assessment
- Simvastatin 80 mg (Type: EXPERIMENTAL): Simvastatin 80 mg/day for 7 days and then switched to simvastatin 20 mg/day for additional 3 weeks, till the endothelial function assessment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: F-18-PSMA-1007 Versus F-18-Fluorocholine PET in Patients With Biochemical Recurrence

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* male with original diagnosis of prostate carcinoma with prior definitive therapy~* suspicion of recurrence (3 consecutive PSA rises and/or PSA rise by 2.0 ng/mL or more above nadir after radiotherapy or cryotherapy and/or PSA rise by greater than 0.2 ng/mL after prostatectomy)~* life expectancy of 6 months or more as judged by the investigator~* willing and able to undergo all study procedures~* informed consent in writing (dated and signed)~Exclusion Criteria:~* age: less than18 years~* contraindications for F-18-Fluorocholine~* contraindications for any of the ingredients of F-18-PSMA-1007~* close affiliation with the investigational site; e.g. first-degree relative of the investigator~* at the time of enrolment into this study, participating in another therapeutic clinical trial or has completed study participation in another therapeutic clinical trial within 5 days of enrolment into this trial~* having been previously enrolled in this clinical trial~* mental conditions rendering the subject incapable to understand the nature, scope, and consequences of the trial~* being clinically unstable or requiring emergency treatment~* being considered a vulnerable person

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- F-18-PSMA-1007 (Type: EXPERIMENTAL): Patients will receive F-18-PSMA-1007 PET/CT first, followed by F-18-Fluorocholine PET/CT.
- F-18-Fluorocholine (Type: ACTIVE_COMPARATOR): Patients will receive F-18-Fluorocholine PET/CT first, followed by F-18-PSMA-1007 PET/CT.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Short and Long Term Multiple Outcomes in Persons With Multiple Sclerosis Treated by Fampridine.

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* MS diagnostic regarding the modified McDonald criteria~* EDSS status between 4.0 and 6.5~* patients able to walk during 6 minutes~Exclusion Criteria:~* increasing MS symptoms during the previous 60 days~* history of epilepsy or epileptic seizure~* immunotherapy change in the previous 60 days~* beginning anti-spastic treatment in the previous 30 days~* beginning treatment that is able to decrease fatigue symptoms in the previous 30 days~* modification of the rehabilitation program during the study~* renal insufficiency (creatinine clearance \<80ml.min-1 given by the Cockroft-Gault formula)~* concomitant treatment by organic cation transporter 2 inhibitor~* hypersensitivity to fampridine

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- Fampridine responder (Type: EXPERIMENTAL): Persons who have been diagnosed as Multiple Sclerosis according to Mc Donald Criteria : person with Multiple Sclerosis (PwMS).~Fampridine was prescribed according to the guidelines issued by the French National Security Agency of Medicines and Health Products (ANSM) at the dose of 10 mg twice a day. According to official ANSM guidelines, the prescription is initially limited to 2 weeks of therapy, at which point a new assessment is performed by the medical practitioner to evaluate the clinical benefits. Fampridine responder is a PwMS with an improvement in the judgment of the practitioner.
- Fampridine non responder (Type: ACTIVE_COMPARATOR): Persons who have been diagnosed as Multiple Sclerosis according to Mc Donald Criteria : person with Multiple Sclerosis (PwMS).~Fampridine was prescribed according to the guidelines issued by the French National Security Agency of Medicines and Health Products (ANSM) at the dose of 10 mg twice a day. According to official ANSM guidelines, the prescription is initially limited to 2 weeks of therapy, at which point a new assessment is performed by the medical practitioner to evaluate the clinical benefits. Fampridine non responder is a PwMS without any improvement in the judgment of the practitioner.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Measles, Mumps, Rubella Vaccination in Juvenile Idiopathic Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* all subtypes of JIA according to ILAR criteria~* ages 4 to 9 (before the scheduled booster, normally administered at age 9 in the Netherlands)~* 5 healthy adults (aged 18 to 65y)~Exclusion Criteria:~* use of Infliximab (Remicade, anti-Tumor Necrosis Factor (TNF) alpha therapy).~* primary immunodeficiency~* fever less than 48 hour prior to vaccination (vaccination will be postponed for 1 month)~* evidence of viral or bacterial infection less than 48hours prior to vaccination (vaccination will be postponed for 1 month)~* methylprednisolone pulse therapy less than 1 month prior to vaccination (vaccination will be postponed for 1 month)~* transfusion of blood or blood products (e.g. intravenous immunoglobulins (IVIG)) in the 3 months prior to vaccination (vaccination will be postponed for 3 months)

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 9 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): Measles, mumps, rubella booster vaccination within 3 months after randomisation
- 2 (Type: NO_INTERVENTION): Booster vaccination performed by regular health authorities at age 9; at least 1 year after randomisation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trial of Pneumococcal Vaccine Schedules in Ho Chi Minh City, Vietnam

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2/PHASE3
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~* Aged between 2 months and 2 months plus 2 weeks (Arms A-F) or aged between 18 months and 18 months plus 2 weeks (Arm G)~* No significant maternal or perinatal history~* Born at or after 36 weeks gestation~* Written and signed informed consent from parent/legal guardian~* Lives within approximately 30 minutes of the commune health centre~* Family anticipates living in the study area for the next 22 months (Arms A-F) or 6 months (Arm G)~* Has received three doses of either Infanrix-hexa or Quinvaxem in infancy (Arm G)~Exclusion Criteria:~* Known allergy to any component of the vaccine~* Allergic reaction or anaphylactic reaction to any previous vaccine~* Known immunodeficiency disorder~* Known HIV-infected mother~* Known thrombocytopenia or coagulation disorder~* On immunosuppressive medication~* Administration or planned administration of any immunoglobulin or blood product since birth~* Severe birth defect requiring ongoing medical care~* Chronic or progressive disease~* Seizure disorder~* History of invasive pneumococcal, meningococcal or Haemophilus influenzae type b diseases, or tetanus, measles, pertussis or diphtheria infections~* Receipt of any 2 month vaccines through the EPI program (Arms A-F) or receipt of PCV (Arm G)~* Family plans on giving the infant Quinvaxem or oral polio vaccine (Arms A-F)

- Gender: ALL
- Minimum Age: 60 Days
- Maximum Age: 74 Days
- Healthy Volunteers: t

Study Arms:
- A: 3+1 PCV10 (Type: ACTIVE_COMPARATOR): PCV10 administered at 2, 3, 4 and 9 months of age
- B: 3+0 PCV10 (Type: EXPERIMENTAL): PCV10 administered at 2, 3 and 4 months of age
- C: 2+1 PCV10 (Type: EXPERIMENTAL): PCV10 administered at 2, 4 and 9 months of age
- D: 1+1 PCV10 (Type: EXPERIMENTAL): PCV10 administered at 2 and 6 months of age
- E: 2+1 PCV13 (Type: EXPERIMENTAL): PCV13 administered at 2, 4 and 9 months of age
- F: control (Type: NO_INTERVENTION): No infant PCV vaccination. PCV10 administered at 18 and 24 months of age
- G: control (Type: NO_INTERVENTION): Recruited at 18 months of age (non-randomised). PCV10 administered at 24 months of age

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of KCC Peptide Application in the Colon

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SCREENING
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects felt to be at increased risk for CRC and colonic polyps~OR~-Subjects with known colonic adenomas scheduled for colonic resection~OR~* Subjects who are scheduled for outpatient colonoscopy for follow up surveillance of IBD with known dysplasia or who are at high risk for high grade dysplasia.~* Subjects who are scheduled for outpatient colonoscopy in the medical procedures unit at the University of Michigan Health Center~* All subjects who are medically cleared for the procedure (e.g. washout for anticoagulants, co-morbidities) who meet the inclusion/exclusion criteria will be included. Standard practice guidelines for safely proceeding with the procedure will be sufficient for our study~* Adults aged 18 to 100 years~* Willing and able to sign informed consent~* The effects of Colon KCC Heptapeptide (5-FITC-labeled peptide) on the developing human fetus are unknown. For this reason, women of childbearing potential must have a negative pregnancy test on the day of the procedure prior to receiving the Colon KCC Heptapeptide (5-FITC-labeled peptide agent) or be post-menopausal. Post-menopausal women are defined as post-hysterectomy, or over 40 and at least 18 months without menses and not on birth-control.~Exclusion Criteria:~* Subjects with known allergy or negative reaction to fluorescein or derivatives.~* Subjects on active chemotherapy or radiation treatment~* Pregnant or trying to conceive

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- peptide application (Type: EXPERIMENTAL): Investigational Agent Administration~* KCCFPAQ-GGGSK-(5-FITC)-NH2~* 1.2 mg lyophilized powder per single-use amber vial~* Lyophilized powder reconstituted with 10 mL of 0.9% NaCl~* Final concentration of 76.4 μM for single, one-time topical application~* The entire 10 mL solution will be sprayed topically onto area of interest by the Clinical Research Associate (CRA)/physician during the procedure through a standard endoscopy spray catheter (Olympus Medical, Tokyo Japan, PW-5V-1)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study Comparing Use of Manual and Power Bone Marrow Aspiration and Biopsy Devices in Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Informed consent and assent for minors over the age of seven years must be obtained before any trial-related activities are initiated~* Patients requiring bone marrow aspirations and/or biopsies as part of standard diagnosis and treatment~* Treated at Christus Santa Rosa Children's hospital~* Age 2 to 18 years~* Male or female~* Supportive family with willingness to participate in completing questionnaires~* English or Spanish primary language~Exclusion Criteria:~* Patients who are pregnant~* Patients with hemorrhagic disorders such as congenital coagulation factor deficiencies disseminated intravascular coagulation and concomitant use of anticoagulants~* Patients with a skin infection or recent radiation therapy at the sampling site~* Patients with bone disorders such as osteomyelitis or osteogenesis imperfecta

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Manual bone marrow aspiration and biopsy procedure (Type: ACTIVE_COMPARATOR): Manual bone marrow aspiration and biopsy device
- Powered bone marrow aspiration and biopsy procedure (Type: ACTIVE_COMPARATOR): Powered bone marrow aspiration and biopsy device

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete